EA201990688A1 - Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение - Google Patents
Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применениеInfo
- Publication number
- EA201990688A1 EA201990688A1 EA201990688A EA201990688A EA201990688A1 EA 201990688 A1 EA201990688 A1 EA 201990688A1 EA 201990688 A EA201990688 A EA 201990688A EA 201990688 A EA201990688 A EA 201990688A EA 201990688 A1 EA201990688 A1 EA 201990688A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- crystalline form
- formula
- polymorphic forms
- producing
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 239000013078 crystal Substances 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 239000002075 main ingredient Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
В настоящем изобретении раскрываются полиморфные формы соединения формулы I, содержащие их фармацевтические композиции, способ их получения и их применение. Соединение формулы I по настоящему изобретению является таким, как показано в формуле I, кристаллическая форма которого может представлять собой кристаллическую форму 1, кристаллическую форму 2, кристаллическую форму 3, кристаллическую форму 5, кристаллическую форму 6 или кристаллическую форму 7. Все кристаллические формы соединения формулы I в настоящем изобретении характеризуются хорошей стабильностью кристаллов и химической стабильностью, а снижение чистоты их основного ингредиента составляет менее 2%. Способ получения по настоящему изобретению можно применять для получения различных кристаллических форм соединения формулы I с высокой чистотой, подходящих для крупномасштабного производства.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610866253 | 2016-09-29 | ||
PCT/CN2017/104506 WO2018059556A1 (zh) | 2016-09-29 | 2017-09-29 | 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201990688A1 true EA201990688A1 (ru) | 2019-08-30 |
Family
ID=61763329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201990688A EA201990688A1 (ru) | 2016-09-29 | 2017-09-29 | Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение |
Country Status (19)
Country | Link |
---|---|
US (2) | US11053224B2 (ru) |
EP (1) | EP3502105B8 (ru) |
JP (2) | JP7253491B2 (ru) |
KR (1) | KR102289684B1 (ru) |
CN (1) | CN108884080B (ru) |
AU (1) | AU2017336889B2 (ru) |
BR (1) | BR112019006023A2 (ru) |
CA (1) | CA3035124A1 (ru) |
EA (1) | EA201990688A1 (ru) |
ES (1) | ES2914294T3 (ru) |
HK (1) | HK1257194A1 (ru) |
IL (2) | IL265266B1 (ru) |
MY (1) | MY194364A (ru) |
PH (1) | PH12019500681A1 (ru) |
PL (1) | PL3502105T3 (ru) |
SG (1) | SG11201901962QA (ru) |
TW (1) | TWI647224B (ru) |
WO (1) | WO2018059556A1 (ru) |
ZA (1) | ZA201901717B (ru) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3502105T3 (pl) * | 2016-09-29 | 2022-07-11 | Equinox Sciences, Llc. | Postać polimorficzna związku stanowiącego inhibitor kinazy, zawierająca ją kompozycja farmaceutyczna oraz sposób jej wytwarzania i jej zastosowanie |
BR112022018815A2 (pt) | 2020-03-25 | 2022-11-29 | Ocular Therapeutix Inc | Implante ocular contendo um inibidor de tirosina cinase |
BR112023018649A2 (pt) * | 2021-03-16 | 2023-10-10 | Hk Inno N Corp | Forma cristalina e método para preparar uma forma cristalina |
JP7138982B1 (ja) | 2021-09-24 | 2022-09-20 | 東海物産株式会社 | アンセリンの結晶及びその製造方法 |
WO2023173093A1 (en) | 2022-03-11 | 2023-09-14 | EyePoint Pharmaceuticals, Inc. | Continuous dosing regimen for treatment of a condition of the eye |
WO2023173088A1 (en) | 2022-03-11 | 2023-09-14 | EyePoint Pharmaceuticals, Inc. | Method of preventing age-related macular degeneration by administering an ocular drug delivery insert |
WO2023173095A1 (en) | 2022-03-11 | 2023-09-14 | EyePoint Pharmaceuticals, Inc. | Method of treating wet age-related macular degeneration |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003031438A1 (en) * | 2001-10-10 | 2003-04-17 | Sugen, Inc. | 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors |
CA2662902C (en) * | 2006-09-15 | 2015-11-24 | Xcovery, Inc. | Kinase inhibitor compounds |
WO2008134909A1 (de) * | 2007-05-07 | 2008-11-13 | Baumer Electric Ag | Akustischer wandler |
US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
US8466190B2 (en) * | 2008-04-16 | 2013-06-18 | Natco Pharma Limited | Polymorphic forms of Sunitinib base |
US8829039B2 (en) * | 2008-05-23 | 2014-09-09 | Shanghai Institute Of Pharmaceutical Industry | Dihydroindolinone derivatives |
EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
EP2264027A1 (en) * | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
CN106928114B (zh) * | 2015-12-31 | 2020-07-28 | 韶远科技(上海)有限公司 | 含有脲基的环状手性氨基类化合物及其可放大工艺和用途 |
PL3502105T3 (pl) * | 2016-09-29 | 2022-07-11 | Equinox Sciences, Llc. | Postać polimorficzna związku stanowiącego inhibitor kinazy, zawierająca ją kompozycja farmaceutyczna oraz sposób jej wytwarzania i jej zastosowanie |
-
2017
- 2017-09-29 PL PL17855006T patent/PL3502105T3/pl unknown
- 2017-09-29 WO PCT/CN2017/104506 patent/WO2018059556A1/zh unknown
- 2017-09-29 TW TW106133830A patent/TWI647224B/zh active
- 2017-09-29 CA CA3035124A patent/CA3035124A1/en active Pending
- 2017-09-29 SG SG11201901962QA patent/SG11201901962QA/en unknown
- 2017-09-29 US US16/338,357 patent/US11053224B2/en active Active
- 2017-09-29 MY MYPI2019000596A patent/MY194364A/en unknown
- 2017-09-29 AU AU2017336889A patent/AU2017336889B2/en active Active
- 2017-09-29 JP JP2019538551A patent/JP7253491B2/ja active Active
- 2017-09-29 KR KR1020197008752A patent/KR102289684B1/ko active IP Right Grant
- 2017-09-29 EA EA201990688A patent/EA201990688A1/ru unknown
- 2017-09-29 IL IL265266A patent/IL265266B1/en unknown
- 2017-09-29 EP EP17855006.7A patent/EP3502105B8/en active Active
- 2017-09-29 BR BR112019006023A patent/BR112019006023A2/pt unknown
- 2017-09-29 IL IL311631A patent/IL311631A/en unknown
- 2017-09-29 ES ES17855006T patent/ES2914294T3/es active Active
- 2017-09-29 CN CN201780008042.1A patent/CN108884080B/zh active Active
-
2018
- 2018-12-18 HK HK18116171.7A patent/HK1257194A1/zh unknown
-
2019
- 2019-03-19 ZA ZA201901717A patent/ZA201901717B/en unknown
- 2019-03-28 PH PH12019500681A patent/PH12019500681A1/en unknown
-
2021
- 2021-06-15 US US17/348,482 patent/US20220356173A1/en active Pending
-
2023
- 2023-03-28 JP JP2023052465A patent/JP2023082086A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201815785A (zh) | 2018-05-01 |
AU2017336889B2 (en) | 2021-11-25 |
US20220356173A1 (en) | 2022-11-10 |
EP3502105B8 (en) | 2022-06-01 |
CN108884080A (zh) | 2018-11-23 |
IL265266A (en) | 2019-05-30 |
ES2914294T3 (es) | 2022-06-08 |
EP3502105B1 (en) | 2022-03-30 |
MY194364A (en) | 2022-11-29 |
PH12019500681A1 (en) | 2019-11-25 |
HK1257194A1 (zh) | 2019-10-18 |
KR102289684B1 (ko) | 2021-08-12 |
BR112019006023A2 (pt) | 2019-06-18 |
JP7253491B2 (ja) | 2023-04-06 |
IL265266B1 (en) | 2024-04-01 |
JP2023082086A (ja) | 2023-06-13 |
US11053224B2 (en) | 2021-07-06 |
AU2017336889A1 (en) | 2019-04-11 |
TWI647224B (zh) | 2019-01-11 |
SG11201901962QA (en) | 2019-04-29 |
CN108884080B (zh) | 2020-10-27 |
JP2019529568A (ja) | 2019-10-17 |
EP3502105A4 (en) | 2020-04-15 |
KR20190039823A (ko) | 2019-04-15 |
WO2018059556A1 (zh) | 2018-04-05 |
ZA201901717B (en) | 2019-11-27 |
IL311631A (en) | 2024-05-01 |
CA3035124A1 (en) | 2018-04-05 |
US20190233403A1 (en) | 2019-08-01 |
EP3502105A1 (en) | 2019-06-26 |
PL3502105T3 (pl) | 2022-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201990688A1 (ru) | Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение | |
EA202090917A1 (ru) | Получение псилоцибина, различных полиморфных форм, промежуточных соединений, составов и их применение | |
EA201891770A1 (ru) | Малеатная соль агониста tlr7, ее кристаллические формы c, d и e, способы получения и применение малеатной соли и кристаллических форм | |
EA201890752A1 (ru) | Способ получения противогрибковых соединений | |
EA201690915A1 (ru) | Производное n-бензилтриптантрина, а также способ его получения и применение | |
EA202091016A1 (ru) | Пиримидиновое соединение в качестве ингибитора jak киназы | |
EA201592144A1 (ru) | Производное фенола, способ его получения и его применение в медицине | |
AR063710A1 (es) | Proceso para la preparacion de acido 6-(3-cloro-2-fluorbencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolon-3-carboxilico como inhibidores de integrasa del hiv e intermediarios de sintesis del mismo y composiciones que lo comprenden. | |
IN2014MN01521A (ru) | ||
EA201201294A1 (ru) | Гидрат гидрохлорида агомелатина и его получение | |
PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
EA201690072A1 (ru) | Состав, содержащий гиполипидемическое средство | |
NZ738836A (en) | Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid | |
SG11201906688VA (en) | Novel ester compounds, method for the production thereof and use thereof | |
EA202190880A1 (ru) | Кристаллическая форма морфолинохиназолинового соединения, способ ее получения и ее применение | |
PH12015502684B1 (en) | New compounds having triple activities of thrombolysis, antithrombotic and radical scavenging, and synthesis, nano-structure and use thereof | |
MA39715A (fr) | Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation | |
MX354648B (es) | Materiales zeoliticos y metodos para su preparacion utilizando compuestos alqueniltrialquilamonio. | |
EA201990237A1 (ru) | Новые способы получения стимуляторов растворимой гуанилатциклазы | |
MY185235A (en) | New crystalline form vii of agomelatine, preparation method and use thereof and pharmaceutical composition containing same | |
WO2015128882A3 (en) | Crystalline forms of n-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide and process for the preparation thereof | |
EA201990236A1 (ru) | Новые способы получения стимуляторов растворимой гуанилатциклазы | |
MA41186B1 (fr) | Nouvelles formes de cristal du sel monosodique de foramsulfuron | |
CA2928305C (en) | A crystalline anhydrous form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof | |
EA202190330A1 (ru) | Способ получения полиморфной формы робенакоксиба |